RT Journal Article
SR Electronic
T1 Human Epidemiology and RespOnse to SARS-CoV-2 (HEROS): Objectives, Design and Enrollment Results of a 12-City Remote Observational Surveillance Study of Households with Children using Direct-to-Participant Methods
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.09.22277457
DO 10.1101/2022.07.09.22277457
A1 Fulkerson, Patricia C.
A1 Lussier, Stephanie J.
A1 Bendixsen, Casper G.
A1 Castina, Sharon M.
A1 Gebretsadik, Tebeb
A1 Marlin, Jessica S.
A1 Russell, Patty B.
A1 Seibold, Max A.
A1 Everman, Jamie L.
A1 Moore, Camille M.
A1 Snyder, Brittney M.
A1 Thompson, Kathy
A1 Tregoning, George S.
A1 Wellford, Stephanie
A1 Arbes, Samuel J.
A1 Bacharier, Leonard B.
A1 Calatroni, Agustin
A1 Camargo, Carlos A.
A1 Dupont, William D.
A1 Furuta, Glenn T.
A1 Gruchalla, Rebecca S.
A1 Gupta, Ruchi S.
A1 Hershey, Gurjit Khurana
A1 Jackson, Daniel J.
A1 Johnson, Christine C.
A1 Kattan, Meyer
A1 Liu, Andrew H.
A1 Murrison, Liza
A1 O’Connor, George T.
A1 Phipatanakul, Wanda
A1 Rivera-Spoljaric, Katherine
A1 Rothenberg, Marc E.
A1 Seroogy, Christine M.
A1 Teach, Stephen J.
A1 Zoratti, Edward M.
A1 Togias, Alkis
A1 Hartert, Tina V.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/07/10/2022.07.09.22277457.abstract
AB The Human Epidemiology and Response to SARS-CoV-2 (HEROS) is a prospective multi-city 6-month incidence study which was conducted from May 2020-February 2021. The objectives were to identify risk factors for SARS-CoV-2 infection and household transmission among children and people with asthma and allergic diseases, and to use the host nasal transcriptome sampled longitudinally to understand infection risk and sequelae at the molecular level. To overcome challenges of clinical study implementation due to the coronavirus pandemic, this surveillance study used direct-to-participant methods to remotely enroll and prospectively follow eligible children who are participants in other NIH-funded pediatric research studies and their household members. Households participated in weekly surveys and biweekly nasal sampling regardless of symptoms. The aim of this report is to widely share the methods and study instruments and to describe the rationale, design, execution, logistics and characteristics of a large, observational, household-based, remote cohort study of SARS-CoV-2 infection and transmission in households with children. The study enrolled a total of 5,598 individuals, including 1,913 principal participants (children), 1,913 primary caregivers, 729 secondary caregivers and 1,043 other household children. This study was successfully implemented without necessitating any in-person research visits and provides an approach for rapid execution of clinical research.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.clinicaltrials.gov/ct2/show/NCT04375761 Funding StatementThis study was funded by NIAID and grants: AI024156, AI051598, UG3OD023282, R01AI127507, 3U19AI070235-14S1, 5UM1AI114271, 3U19AI070235-14S1, U19 AI104317, PO1HL70381, 1UL1TR001430, 5UM1AI114271, UM1AI114271, 3U54AI117804-06S1, 3U54AI117804-07S1, U01 AI 110397, R01 HL 137192, K24 AI 106822, U10 HL109172, 3UM1AI114271-06S1, 3UM1AI114271-07S1, 3UM1AI114271-06S1, 5UM1AI114271, 3U54AI117804-06S1, 3U54AI117804-07S1, 3R01AI130348-04S1, 5UM1AI114271, 3UM1AI14271-07S1, UM1 AI11427, 5UM1AI114271, U19 AI 095227-S2, U19 AI 095227- S1, UL1 TR002243, 3R01AI130348-04S1, 3PO1AI089473-07S1, AI089473, UG3OD023282, 3U19AI070235-14S1, NIH 3UM1AI151958-01S1, NIH 3UM1AI151958-02S1, 1UM2AI117870, U01 AI 110397, R01 HL 137192, K24 AI 106822, U10 HL109172, U19 AI 095227- S1, AI050681, AI089473, UG3OD023282, R01AI127507, U19 AI104317, UH3 OD023282.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee/Institutional Review Board (IRB) of Vanderbilt University, which was designated as the study single IRB, reviewed the study protocol and determined that the study satisfied criteria for the public health surveillance exception [45CFR46.102(I)(2)].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests may be made for use of data from the HEROS study to the NIAID. A protocol committee will review requests as use of HEROS data is restricted to studies focused on SARS-CoV-2 as this study was conducted as public health surveillance of SARS-CoV-2.IQR(interquartile range)PCR(polymerase chain reaction)SARS-CoV-2(severe acute respiratory syndrome coronavirus 2)SD(standard deviation)